Issue Date: November 22, 2010
Lupus Drug Nears FDA Approval
An FDA advisory committee has recommended approval for Benlysta, a monoclonal antibody to treat lupus being developed by Human Genome Sciences and GlaxoSmithKline. If approved, Benlysta would be the first new drug in decades to treat lupus, a chronic disease that occurs when immune system antibodies attack healthy tissues. It would also be Human Genome’s first marketed product. Benlysta works by blocking B-lymphocyte stimulator, a protein that is overexpressed . . .
To view the rest of this content, please log in with your ACS ID.
- Chemical & Engineering News
- ISSN 0009-2347
- Copyright © American Chemical Society